Biosimilars and Innovator Glycans

Discover key insights on biosimilar and innovator glycan characterization methods, including comparisons of analytical techniques, glycosylation impacts on therapeutic efficacy, and patient outcomes.

Webinar Summary

N-Glycan Characterization and the Future of Method Standardization N-glycans are omnipresent in the Fc region of monoclonal antibody products. Modifications to a glycan profile can impact a protein’s stability/folding, binding affinities, effector functions, clearance rates, and/or immunogenicity. Their characterization is critical to ensuring efficacy and safety in patients. The multitude of glycan characterization methods, each with different levels of sensitivity and reliability, complicates standardization efforts. To tackle this, we’ve conducted comparative glycan analysis studies, examining various innovator mAbs, their biosimilars, and different characterization techniques for NIST mAb.

This session was recorded in February 2024.

Key Learning Objectives

Comparison of innovator anti-TNF⍺ mAbs (Humira®, Remicade®, Simponi Aria®) and trastuzumab biosimilars (Kanjinti®, Ogivri®) with reference drugs.
Highlighting the impact of glycan differences in mAbs on patient experience.
Suggesting future standardization approaches for glycan characterization in mAbs.